JP2009505988A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009505988A5 JP2009505988A5 JP2008527009A JP2008527009A JP2009505988A5 JP 2009505988 A5 JP2009505988 A5 JP 2009505988A5 JP 2008527009 A JP2008527009 A JP 2008527009A JP 2008527009 A JP2008527009 A JP 2008527009A JP 2009505988 A5 JP2009505988 A5 JP 2009505988A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- och
- sch
- independently
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 67
- 125000001072 heteroaryl group Chemical group 0.000 claims 58
- 125000000623 heterocyclic group Chemical group 0.000 claims 49
- 125000003710 aryl alkyl group Chemical group 0.000 claims 46
- 125000000547 substituted alkyl group Chemical group 0.000 claims 42
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 42
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 41
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 40
- 125000003107 substituted aryl group Chemical group 0.000 claims 40
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 39
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 38
- 229910052757 nitrogen Inorganic materials 0.000 claims 34
- 125000001188 haloalkyl group Chemical group 0.000 claims 32
- 125000005843 halogen group Chemical group 0.000 claims 29
- -1 cyano, nitro, Guanidino Chemical group 0.000 claims 25
- 125000004404 heteroalkyl group Chemical group 0.000 claims 24
- 125000004438 haloalkoxy group Chemical group 0.000 claims 19
- 125000003545 alkoxy group Chemical group 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 11
- 239000000651 prodrug Substances 0.000 claims 11
- 229940002612 prodrug Drugs 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 239000012453 solvate Substances 0.000 claims 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 125000004432 carbon atom Chemical group C* 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 7
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 239000000126 substance Substances 0.000 claims 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 6
- 101100516572 Caenorhabditis elegans nhr-8 gene Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 6
- 125000004414 alkyl thio group Chemical group 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 2
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 1
- RGICCULPCWNRAB-UHFFFAOYSA-N 2-[2-(2-hexoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCOCCOCCOCCO RGICCULPCWNRAB-UHFFFAOYSA-N 0.000 claims 1
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 claims 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 0 *c1ncc(-c2cccnc2S)[n]1* Chemical compound *c1ncc(-c2cccnc2S)[n]1* 0.000 description 10
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70922805P | 2005-08-18 | 2005-08-18 | |
| US60/709,228 | 2005-08-18 | ||
| PCT/US2006/031281 WO2007021877A1 (en) | 2005-08-18 | 2006-08-10 | Imidazole compounds that modulate hsp90 activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009505988A JP2009505988A (ja) | 2009-02-12 |
| JP2009505988A5 true JP2009505988A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2009-10-01 |
| JP5683787B2 JP5683787B2 (ja) | 2015-03-11 |
Family
ID=37434295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008527009A Expired - Fee Related JP5683787B2 (ja) | 2005-08-18 | 2006-08-10 | Ｈｓｐ９０活性を調節するイミダゾール化合物 |
Country Status (7)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103554042B (zh) * | 2004-11-18 | 2016-08-10 | Synta医药公司 | 调节hsp90活性的三唑化合物 |
| AU2006279794B2 (en) | 2005-08-12 | 2011-04-07 | Synta Pharmaceuticals Corp. | Pyrazole compounds that modulate HSP90 activity |
| AU2006279887B2 (en) * | 2005-08-18 | 2011-06-16 | Synta Pharmaceuticals Corp. | Imidazole compounds that modulate Hsp90 activity |
| WO2007094819A2 (en) | 2005-08-18 | 2007-08-23 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| US20070250391A1 (en) * | 2006-04-05 | 2007-10-25 | Prade Hendrik D | Merchandising system and method for food and non-food items for a meal kit |
| US20070259820A1 (en) * | 2006-05-03 | 2007-11-08 | The Regents Of The University Of Michigan | Methods and reagents for activating heat shock protein 70 |
| AU2007267852A1 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Compounds that modulate Hsp90 activity and methods for identifying same |
| EP2034995A2 (en) | 2006-05-25 | 2009-03-18 | Synta Pharmaceuticals Corporation | Method for treating proliferative disorders associated with protooncogene products |
| EP2026797A2 (en) | 2006-05-25 | 2009-02-25 | Synta Pharmaceuticals Corporation | Method for treating non-hodgkin's lymphoma |
| EP2034996A2 (en) | 2006-05-25 | 2009-03-18 | Synta Pharmaceuticals Corporation | Triazole compounds that modulate hsp90 activity |
| CA2653329C (en) | 2006-05-25 | 2018-01-16 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| WO2008112199A1 (en) * | 2007-03-12 | 2008-09-18 | Synta Pharmaceuticals Corp. | Method for inhibiting topoisomerase ii |
| BRPI0815116A2 (pt) * | 2007-08-13 | 2015-01-27 | Synta Pharmaceuticals Corp | Compostos de triazol que modulam a atividade da hsp90 |
| CN101821247A (zh) * | 2007-10-12 | 2010-09-01 | 艾科尔公司 | 作为hsp90抑制剂的抗癌用5-(2-羟基苯基)四唑化合物 |
| GB0722680D0 (en) * | 2007-11-19 | 2007-12-27 | Topotarget As | Therapeutic compounds and their use |
| BRPI0905952A2 (pt) | 2008-02-04 | 2015-06-30 | Mercury Therapeutics | Composto e sais do mesmo e compição farmacêutica |
| WO2009139916A1 (en) * | 2008-05-16 | 2009-11-19 | Synta Pharmaceuticals Corp. | Tricyclic triazole compounds that modulate hsp90 activity |
| WO2009148599A1 (en) | 2008-06-04 | 2009-12-10 | Synta Pharmaceuticals Corp. | Pyrrole compunds that modulate hsp90 activity |
| WO2009158026A1 (en) | 2008-06-27 | 2009-12-30 | Synta Pharmaceuticals Corp. | Hydrazonamide compounds that modulate hsp90 activity |
| WO2010017545A2 (en) | 2008-08-08 | 2010-02-11 | Synta Pharamceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| EP2328893B1 (en) * | 2008-08-08 | 2013-03-20 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| DE102009043260A1 (de) * | 2009-09-28 | 2011-04-28 | Merck Patent Gmbh | Pyridinyl-imidazolonderivate |
| EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| JP2012087113A (ja) * | 2010-09-22 | 2012-05-10 | Daicel Corp | フェニル酢酸化合物 |
| WO2013006864A2 (en) | 2011-07-07 | 2013-01-10 | Synta Pharmaceuticals Corp. | Treating cancer with hsp90 inhibitory compounds |
| WO2013067165A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
| CA2853799A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| WO2013074594A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
| US20150119395A1 (en) * | 2012-04-04 | 2015-04-30 | Synta Pharmaceuticals Corp. | Novel triazole compounds that modulate hsp90 activity |
| WO2015153933A1 (en) | 2014-04-03 | 2015-10-08 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| ES2827523T3 (es) * | 2015-03-11 | 2021-05-21 | Riken | Agente terapéutico para la leucemia intratable |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3303199A (en) * | 1963-07-15 | 1967-02-07 | Geigy Chem Corp | Certain imidazolone derivatives and process for making same |
| JPS5343958B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1972-07-29 | 1978-11-24 | ||
| US4160841A (en) | 1977-01-31 | 1979-07-10 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles |
| JPS5528907A (en) | 1978-08-21 | 1980-02-29 | Kaken Pharmaceut Co Ltd | Novel 5-(pyridyl)-2-mercaptoimidazole derivative, its preparation,and medicine containing thereof as effective component |
| DE3042466A1 (de) | 1980-11-11 | 1982-06-16 | A. Nattermann & Cie GmbH, 5000 Köln | N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
| DE3504677A1 (de) | 1985-02-12 | 1986-08-14 | A. Nattermann & Cie GmbH, 5000 Köln | Neue imidazol-2-yloxyalkansaeuren und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
| JP3169413B2 (ja) | 1992-01-31 | 2001-05-28 | エーザイ株式会社 | イミダゾール誘導体 |
| US5438150A (en) | 1994-04-26 | 1995-08-01 | Syntex (U.S.A.) Inc. | Process for making 1-benzocycloalkyl-1,3-dihydroimidazole-2-thione derivatives |
| US5538988A (en) | 1994-04-26 | 1996-07-23 | Martinez; Gregory R. | Benzocycloalkylazolethione derivatives |
| TW467902B (en) | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
| AUPO527597A0 (en) | 1997-02-24 | 1997-03-20 | Fujisawa Pharmaceutical Co., Ltd. | Novel heterocyclic compounds |
| AR017200A1 (es) | 1997-12-23 | 2001-08-22 | Astrazeneca Ab | Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos |
| JP2000284412A (ja) | 1999-03-30 | 2000-10-13 | Fuji Photo Film Co Ltd | 熱現像写真材料 |
| SE9902387D0 (sv) | 1999-06-22 | 1999-06-22 | Astra Ab | New pharmaceutically active compounds |
| US7473695B2 (en) | 2001-10-22 | 2009-01-06 | Mitsubishi Tanabe Pharma Corporation | 4-imidazolin-2-one compounds |
| MXPA04003729A (es) * | 2001-10-22 | 2004-07-23 | Tanabe Seiyaku Co | Compuestos de 4-imidazolin-2-ona. |
| GB0227948D0 (en) * | 2002-11-29 | 2003-01-08 | Cipla Ltd | Pharmaceutical combinations comprising b-2 adrenoreceptor agonists and xanthines |
| GB0228417D0 (en) | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
| GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| JP2005084612A (ja) | 2003-09-11 | 2005-03-31 | Fuji Photo Film Co Ltd | ハロゲン化銀乳剤、ハロゲン化銀感光材料、および熱現像感光材料 |
| WO2005044194A2 (en) | 2003-10-28 | 2005-05-19 | Pharmacia Corporation | TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR |
| CN100360508C (zh) * | 2004-07-15 | 2008-01-09 | 浙江大学 | 咪唑-2-酮类化合物及其制备方法和用途 |
| CN103554042B (zh) * | 2004-11-18 | 2016-08-10 | Synta医药公司 | 调节hsp90活性的三唑化合物 |
| AU2006279887B2 (en) * | 2005-08-18 | 2011-06-16 | Synta Pharmaceuticals Corp. | Imidazole compounds that modulate Hsp90 activity |
-
2006
- 2006-08-10 AU AU2006279887A patent/AU2006279887B2/en not_active Ceased
- 2006-08-10 US US11/502,347 patent/US8629285B2/en active Active
- 2006-08-10 EP EP20060801197 patent/EP1951679B1/en active Active
- 2006-08-10 WO PCT/US2006/031281 patent/WO2007021877A1/en active Application Filing
- 2006-08-10 CA CA 2618724 patent/CA2618724A1/en not_active Abandoned
- 2006-08-10 JP JP2008527009A patent/JP5683787B2/ja not_active Expired - Fee Related
- 2006-08-18 TW TW95130375A patent/TWI469970B/zh not_active IP Right Cessation
-
2013
- 2013-12-11 US US14/103,420 patent/US9156794B2/en not_active Expired - Fee Related
-
2015
- 2015-07-13 US US14/797,628 patent/US20160000756A1/en not_active Abandoned